Sunesis Pharmaceuticals, Inc. (SNSS)
(Delayed Data from NSDQ)
$1.37 USD
+0.05 (3.79%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.37 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Viracta Therapeutics, Inc. [SNSS]
Reports for Purchase
Showing records 1 - 20 ( 166 total )
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Vecabrutinib not to progress, SNS-510 elevated
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Data While Pivoting to PDK1 Inhibitor Program; Reit Neutral and Reduce PT to $0.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
400mg data similar to previous cohort
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple upcoming readouts on vecabrutinib
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Data and Diversification of Clinical Pipeline; Reit Neutral and Raising PT to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
300mg suggests activity, but higher doses needed
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Likely Continued Dose Escalation Into 2020; Reit Neutral and Reducing PT to $0.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Vecabrutinib Data Update at EHA Could Be Encouraging
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Data Readout at EHA Could Be Highly Informative; Raising PT to $1.50 Following Successful Capital Raise
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
May Be Closer to the Truth of Vecabrutinib?s Potential but Await Further Clarity; Init With Neutral Rating and $0.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Viracta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2018: 50mg cohort on last patient
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N